References
- Elliott, P. M. 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy. Russian Journal of Cardiology 2015. https://doi.org/10.15829/1560-4071-2015-05-7-57.
- O’Mahony, C.; Jichi, F.; Pavlou, M.; Monserrat, L.; Anastasakis, A.; Rapezzi, C.; Biagini, E.; Gimeno, J. R.; Limongelli, G.; McKenna, W. J.; Omar, R. Z.; Elliott, P. M.; Ortiz-Genga, M.; Fernandez, X.; Vlagouli, V.; Stefanadis, C.; Coccolo, F.; Sandoval, M. J. O.; Pacileo, G.; Masarone, D.; Pantazis, A.; Tome-Esteban, M.; Dickie, S.; Lambiase, P. D.; Rahman, S. A Novel Clinical Risk Prediction Model for Sudden Cardiac Death in Hypertrophic Cardiomyopathy (HCM Risk-SCD). European Heart Journal 2014. https://doi.org/10.1093/eurheartj/eht439.
- Maron, B. J.; Wolfson, J. K.; Epstein, S. E.; Roberts, W. C. Intramural (“Small Vessel”) Coronary Artery Disease in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology 1986. https://doi.org/10.1016/S0735-1097(86)80181-4.
- Eng, C. M.; Fletcher, J.; Wilcox, W. R.; Waldek, S.; Scott, C. R.; Sillence, D. O.; Breunig, F.; Charrow, J.; Germain, D. P.; Nicholls, K.; Banikazemi, M. Fabry Disease: Baseline Medical Characteristics of a Cohort of 1765 Males and Females in the Fabry Registry. Journal of Inherited Metabolic Disease 2007. https://doi.org/10.1007/s10545-007-0521-2.
- Wilcox, W. R.; Oliveira, J. P.; Hopkin, R. J.; Ortiz, A.; Banikazemi, M.; Feldt-Rasmussen, U.; Sims, K.; Waldek, S.; Pastores, G. M.; Lee, P.; Eng, C. M.; Marodi, L.; Stanford, K. E.; Breunig, F.; Wanner, C.; Warnock, D. G.; Lemay, R. M.; Germain, D. P. Females with Fabry Disease Frequently Have Major Organ Involvement: Lessons from the Fabry Registry. Molecular Genetics and Metabolism 2008. https://doi.org/10.1016/j.ymgme.2007.09.013.
- Sims, K.; Politei, J.; Banikazemi, M.; Lee, P. Stroke in Fabry Disease Frequently Occurs before Diagnosis and in the Absence of Other Clinical Events: Natural History Data from the Fabry Registry. Stroke 2009. https://doi.org/10.1161/STROKEAHA.108.526293.
- Namdar, M. Electrocardiographic Changes and Arrhythmia in Fabry Disease. Frontiers in Cardiovascular Medicine 2016, 3 (March), 1–6. https://doi.org/10.3389/fcvm.2016.00007
- Shah, J. S.; Hughes, D. A.; Sachdev, B.; Tome, M.; Ward, D.; Lee, P.; Mehta, A. B.; Elliott, P. M. Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Dabry Disease. American Journal of Cardiology 2005. https://doi.org/10.1016/j.amjcard.2005.05.033.
- Krämer, J.; Niemann, M.; Liu, D.; Hu, K.; MacHann, W.; Beer, M.; Wanner, C.; Ertl, G.; Weidemann, F. Two-Dimensional Speckle Tracking as a Non-Invasive Tool for Identification of Myocardial Fibrosis in Fabry Disease. European Heart Journal 2013. https://doi.org/10.1093/eurheartj/eht098.
- Desnick, R. J.; Brady, R.; Barranger, J.; Collins, A. J.; Germain, D. P.; Goldman, M.; Grabowski, G.; Packman, S.; Wilcox, W. R. Fabry Disease, an under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. Annals of Internal Medicine. 2003. https://doi.org/10.7326/0003-4819-138-4-200302180-00014.
- Germain, D. P.; Fan, J. Q. Pharmacological Chaperone Therapy by Active-Site-Specific Chaperones in Fabry Disease: In Vitro and Pre-clinical Studies. In International Journal of Clinical Pharmacology and Therapeutics; 2009.